Huntington's disease (HD) is a devastating and incurable neurodegenerative disorder characterized by progressive cognitive, psychiatric and motor impairments. Although the disease has been seen as a disorder purely of the brain, there is now emerging evidence that abnormalities outside the central nervous system are commonly seen in HD. Indeed, the mutant huntingtin (mHtt) coded for by the abnormal gene in HD is found in every cell type where its presence has been sought. In particular, there are a number of recent observations in HD patients that mHtt interacts with the immune system with accumulating evidence that changes in the immune system may critically contribute to the pathology of HD. However, the nature of this contribution remains unclear, to the extent that it is not even known whether the immune system has a beneficial or detrimental role in HD patients. In this review, we attempt to bring a novel understanding to the interaction of the immune system to HD pathology, thereby shedding light on its potential pathogenic role. As part of this discussion, we revisit the clinical data on the anti-inflammatory drug trials in HD and propose new experimental approaches to interrogate the role of immunity in this currently incurable disorder.
Introduction
Huntington's disease (HD) is an autosomal-dominant inherited neurodegenerative disorder characterized by marked psychiatric, cognitive and motor impairments. The features of the disease are caused by a CAG codon/polyglutamine repeat expansion in the first exon of the huntingtin gene, which leads to the expression of a mutated form of the huntingtin protein (mHtt) in cells of the central nervous system (CNS).
However, the presence of abnormalities is not restricted to the CNS, but found in several other compartments including the neuroendocrine system, skeletal muscles, cardiovascular system, blood, digestive tract, thyroid, skeleton and genital organs 1 ( Figure 1 ). Understanding this systemic nature of HD is important in better developing models of disease pathogenesis to design disease modifying therapies, as currently the condition can only be treated with drugs that offer varying degrees of symptomatic benefits. [2] [3] [4] At the cellular level, the loss of function of the wild-type protein and toxic gain of function of the mHtt both contribute to the disruption of multiple intracellular pathways, including postsynaptic signaling, apoptosis, transcriptional regulation, protein trafficking and vesicular transport ( Figure 2 ). Consequently, mHtt induces a cascade of events involving excitotoxicity, proteasome impairment, mitochondrial dysfunction, oxidative stress, metabolic impairment, calcium homeostasis dysregulation, apoptosis and autophagy. 5 The combination of these intracellular dysfunctions over time causes the progressive neuronal degeneration that characterizes HD. 6 In this review, we examine the current evidence that the immune system is implicated in the pathogenesis of HD, and that it may be a potential therapeutic target. In particular, we explore the interplay between the peripheral expression of mHtt and the activation of the innate immune response and how this may impact on the disease process.
Inflammation and immunity in HD
Astrocytes and microglia are two types of cells that are remarkably reactive to local environmental changes. They are thus key players in the brain inflammatory response. Under normal conditions, astrocytes are involved in structural, metabolic and synaptic functions, 7 while the microglia are the major intrinsic immunocompetent cells of the central nervous system 8 actively monitoring the parenchymal environment. 9 Early descriptions of some of the major pathological features of HD 10 interestingly reported important regional brain differences in the astrocytic response but this was interpreted as being a reflection of the primary event of neuronal dysfunction and loss. In this respect, it has long been recognized that the neostriatum undergoes early diffuse atrophy; the caudate nucleus being more severely affected than the putamen, with more subtle changes within the cerebral cortex. These morphological changes correlate with the intensity of the astrocytic response and more recently, postmortem studies have also found signs of a similar response with significant accumulation of activated microglia in these same regions. Moreover, the density of these microglia correlates with the severity of the pathology, suggesting a close association between microglial activation and neuronal death. 11 Indeed recent PET studies in HD patients, utilizing the PK11195 ligand with high affinity for peripheral benzodiazepine receptors that are located in activated microglia, also supports the notion that microglial activation is an early event in HD pathogenesis [12] [13] [14] for which more specific mechanisms have been proposed including the activation of the kynurenine pathway within microglia. 15 Altered immune profiles are detectable in the plasma and striatal tissue of HD patients, and seemingly correlate with disease progression. 16 For example, levels of interleukin (IL)-6, IL-8 and tumor necrosis factor-a in the plasma and cerebrospinal fluid of HD patients have been reported to be higher than in non-HD controls. 16 Basal plasma cortisol levels are higher in HD patients, and are independent of adrenocorticotropic hormone levels. 17 In spite of the fact that cortisol is a major immunosuppressor, the levels measured in HD are insufficient for inhibiting the hyperactive immune system. 16 Critically though is the question as to whether there is a contribution of the inflammatory response to neuronal degeneration in HD, as in several other degenerative and neuropsychiatric disorders. There is now emerging data providing compelling evidence for immune abnormalities in HD, which are central to the disease process ( Figure 1 ).
Molecular contribution of mHtt toxicity to inflammation-evidence from animal studies
At the cellular level, neuronal dysfunction has been proposed to be mediated by intermediate stages of polyglutamine aggregates 18 which lead to cytoplasmic and nuclear inclusions of aggregated mHtt that are already present at the onset of the disease. 19 The specific mechanisms linking the abnormally expanded huntingtin with the pathogenesis of HD are not well understood, but experimental data suggest that excitotoxicity, metabolic impairment and oxidative stress are all involved in the neurodegenerative process. 5 Polyglutamine inclusions have been observed in various peripheral tissues and organs of HD animal models (that is, HdhQ150 knock-in, R6/2 at 12 or 14 weeks), although this varies between models. Nevertheless, in most of these transgenic models there is mHtt expression in skeletal muscle fibers, hepatocytes, adrenal glands, kidneys, and cardiac muscle. 20, 21 PolyQ inclusions have also been observed within the submucosal and myenteric plexus (in both Immunity in Huntington's disease D Soulet and F Cicchetti Figure 2 Intracellular targets of mHtt. mHtt that contains a polyQ expansion induces the formation of neuritic, cytoplasmic and nuclear inclusions, leading to dysfunction of the cell, followed ultimately by death. Calcium homeostasis dysregulation has a central role in this cascade of events. Under physiological conditions, glutamate stimulates the entry of calcium through NMDA receptors (1) . mHtt interferes with PSD95 and induces the sensitization of NMDA receptors resulting in a massive entry of calcium (2) . Calcium-dependent proteases (for example, calpains), are thereafter activated (3), cleaving the full-length mHtt to release an N-terminal polyQ stretch (Q) (4). mHtt fragments are ubiquitinated (U) (5) and inefficiently targeted to the proteasome for degradation (6) . Intact cytoplasmic polyQ stretches form aggregates (7), which impair proteasome function. Degradation of the mHtt also takes place by autophagy (8), a process involving the formation of doublemembrane structures called autophagosomes around a portion of the cytoplasm. N-terminal fragments containing the polyQ stretch of polyQ-huntingtin are translocated to the nucleus (9), where they can be ubiquitinated (10) in order to be degraded by the proteasome system (11) . Spared polyQ-huntingtin forms nuclear aggregates (12) , a hallmark of the disease. Soluble polyQ-huntingtin fragments can interact with transcription factors and lead to transcriptional dysregulation. The mHtt has many intracellular targets. For example, it can impair mitochondrial homeostasis (13) and contribute to the release of proapoptotic factors, such as Cyt c. Concomitantly, abnormal mitochondrial function causes a reduction of ATP production and disrupts calcium homeostasis (14) . The abnormal release of calcium from the endoplasmic reticulum (15) also contributes to the massive intracellular calcium build-up (16) , which is associated with oxidative stress, energy metabolism dysfunction and finally cell death. mHtt is known to slow down intracellular trafficking and to reduce vesicular transport (17) . For example, mHtt interacts strongly with HAP1, leading to the detachment of the motor protein from the microtubules (18) . Consequently, vesicular transport is altered, notably the transport of trophic factors such as BDNF. The mHtt interacts also with many proteins involved in exocytosis and endocytosis, and can alter the recycling of vesicles (19) . Finally, it has recently been suggested that extracellular mHtt can penetrate into the cell and promote the formation of aggregates (20) . Abbreviations: ATP, adenosine triphosphate; BDNF, brain-derived neurotrophic factor; Cyt c, cytochrome c; HIPs, huntingtin-interacting proteins; HAPs, huntingtin-associated proteins; mHtt, mutant huntingtin; NMDA, N-methyl-Daspartic acid; Q, polyQ stretch.
the stomach and the duodenum), the serosal ganglia and the smooth muscle fibers of the stomach wall in both HdhQ150 and R6/2 (12 weeks) models (Table 1) . The connective tissue and fibroblasts of the spleen also contain polyQ inclusions in the HdhQ150 and R6/2 12 week models, but not in the R6/2 at 14 weeks. Moffitt et al. also showed sparse polyQ inclusions in Schwann cells of the skin and in brown adipocytes (moderate in the R6/2) in both the HdhQ150 and R6/2 (12 week) mice (Table 1 ).
The recent development of a transgenic mouse in which astrocytes were engineered to express the mHtt, 22 has demonstrated that expressing the mutant protein only in this cell type can drive neurological impairments. As astrocytes are involved in glutamate clearance and thus protect in part against glutamateinduced neurotoxicity, the intricate relationship of mHtt expression with the decrease in glutamate transporter expression observed in this study supports the role of glial mHtt in HD pathology. Previous findings have shown that mHtt reduces glutamate transporter-1 expression in transgenic mice [23] [24] [25] and decreases glutamate transporter-1 mRNA and glutamate uptake in the brains of HD patients. [26] [27] [28] [29] However, this may not be the whole story as the expression on mHtt in astrocytes from R6/2 mice alters both the production and secretion of the chemokine (C-C motif) ligand 5 (CCL5). 30 Given that CCL5 is involved in the development of neurites and in neuronal activity, its reduced availability to neurons contributes to neuronal dysfunction in HD.
In the context of our review, the question on the specific role of astrocytes in immunity and HD needs to be addressed. In pathological conditions, astrocytes can be activated to produce cytokines, but are unlikely to behave as efficient antigenpresenting cells, because the upregulation of major histocompatibility complex class II molecules on this cell type is a rare event. 31 Current knowledge suggests that astrocytes are weak antigen-presenting cells, but can nevertheless promote the Th2 response under certain conditions 31 and thus may have a role in modulating the immune response to the mHtt in other cells within the CNS. As such, the contribution of astrocytes to the immune response in HD deserves further attention, especially to determine whether their immune behavior can be altered when exposed to mHtt and what effect this has on the disease course.
Overall, activation of microglia, the main player of the cerebral innate immune system, can contribute to neuronal death via mechanisms such as the generation of free radical products, 32 N-methyl-D-aspartic acid-mediated excitotoxicity 33 and caspase activation. 34, 35 The identification of new elements or pathways in this network in HD may indeed offer additional inflammatory targets and ultimately be of great therapeutic value in the clinic. In this regard, exciting new research has shown that modulation of cannabinoid receptor 2 attenuates microglial activation and dampens neurodegeneration in HD mice 36 ( Figure 3 ).
Molecular contribution of mHtt toxicity to inflammation-evidence from human data
Huntingtin transcripts are expressed throughout the human body at basal levels. However, they are expressed in immune cells in amounts threefold higher than the mean value calculated for any other organs (Genomics Institute of the Novartis Research Foundation, transcript 202389_s_at). The mHtt transcript may also be preferentially expressed in immune cells because its expression is controlled by the same promoter as for the wild-type huntingtin. Consequently, a more specific impact of the mHtt on the immune system could be predicted with some confidence from the already available observations. Sathasivam et al.
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Immunity in Huntington's disease D Soulet and F Cicchetti mHtt has been reported in monocytes, microglia and astrocytes of HD patients, 16, 22, 37 but the detection of mHtt expression in cell populations outside the CNS has received only limited attention, with a single report describing nuclear inclusions in the postmortem muscle tissue of a HD patient (male; 48 CAG; 43 years of age at death). 38 Interestingly, there is increased complement biosynthesis (for example, C3 and C9) by microglia in the brains of HD patients, and so it has been proposed that the complement system is activated in the membranes of neurons, thus inducing cytotoxicity, which may in turn contribute to neuronal death 39 ( Figure 3 ). The IkB kinase/nuclear factor-kB signaling pathway that triggers IL-6 release is also upregulated by mHtt, potentially participating in neurotoxicity. 40 What are the repercussions of mHtt on the immune system? In Parkinson's disease-a disorder also typified by neurodegeneration, motor and cognitive deficits-there has been recent interests in the observations of a spatio-temporal neuroanatomical expression of Lewy bodies (which are largely composed of a-synuclein) in relation with disease symptomatology. 41, 42 The culprit, a neurotoxic molecule or pathogen, is thought to spread through the body by neuronal retrograde axonal transport and transsynaptic transmission, in a prion-like fashion. 43, 44 Of relevance to our debate is the demonstration that asynuclein also triggers neuroinflammation, which in turn may contribute to neuronal degeneration. 45 The correlation of mHtt and disease expression in various systems, originating in peripheral tissues, is proving very interesting and intriguing. Indeed it can be surmised that the soluble or aggregated forms of mHtt are released on neuronal cell death, and subsequently detected and captured by immune cells as immunogenic molecules. Misfolded mHtt could be sensed as an ''infectious'' protein triggering an immune response in much the same way as other proteins-for example, extracellular amyloid can be taken up by macrophages through a phagocytic or receptor-mediated endocytic process. 46 Remarkably, synthetic polyQ peptides can also be ingested by cells in culture, which can then translocate to the nucleus where they become cytotoxic 47 ( Figure 2 ). Moreover, internalized fibrillar aggregates are able to interact with soluble cytoplasmic proteins. 48 Two hypotheses emerge from these concepts: the release of immunogenic molecules from dying neurons could trigger an immune response, or sensitize the immune cells to the inflammatory environment. Alternatively, the intrinsic microglial expression of the mHtt might compromise their physiological function and exacerbate the release of pro-inflammatory cytokines, quinolinic acid (QA) and oxygen species (Figure 3 ).
Additional potential players
In the discussion of abnormal immunity in HD, other candidates need to be considered, and of these the ubiquitin-proteasome system deserves particular attention. The ubiquitin-proteasome system has an important role in a variety of fundamental cellular processes such as regulation of cell cycle progression, division, development and differentiation, apoptosis, cell trafficking, and importantly, the modulation of the immune and inflammatory responses. In fact, dysregulation of the ubiquitin-proteasome system has been suggested to underlie the pathogenesis of several inherited and acquired diseases, including inflammatory and autoimmune disorders. More specifically, Figure 3 Putative molecular mechanisms of the immune response in Huntington's disease (HD). There are two routes by which we speculate that microglia might contribute to HD pathogenesis. (1) Degenerating neurons trigger inflammation in the brain, thereby releasing mHtt, which can be captured by microglia. (2) Constitutive expression of mHtt by microglia triggers a heightened immune response. Both scenarios can culminate into an activation of immune cells, which trigger the complement system and promote the secretion of proinflammatory cytokines. Moreover, the induction of the kynurenine pathway leads to the release of reactive oxygen species (ROS) and quinolinic acid (QA) production, all of which are harmful to cells (see black arrows). The microglial QA release, in combination with astrocytic deficiencies in glutamate reuptake, exacerbate excitotoxicity in neurons. In addition, mHtt in astrocytes downregulates the expression and secretion of chemokine (C-C motif) ligand 5 (CCL5), thus attenuating its beneficial effects on neurite development and neuronal activity. Reactive microglia could also have a mostly beneficial role through the release of neurotrophic factors and thus directly or indirectly promote neuroprotection (dashed arrows). Downregulation of the cannabinoid receptor 2 (CB2) in HD modulates microglial reactivity. Finally, cell-specific, differential proteasome activity may negatively correlate with the toxicity of the soluble form of mHtt. the proteasome has been shown to regulate inflammatory pathways by controlling the function of macrophages, 49 and of late a very interesting observation by Tydlacka et al. 50 reports on the differential activity of the ubiquitin-proteasome system in neurons vs glia, which might account for the relative extent of accumulation of misfolded proteins between the two different cell types. As neurons are postmitotic cells, it can be hypothesized that astrocytes, which actively divide in response to cerebral changes and injuries, 51 may consequently dilute the cytosolic content of mHtt in daughter cells. 50 As a result, astrocytes may be less sensitive to mHtt than their neuronal counterparts 50 ( Figure 3 ). There is therefore accumulating evidence that the immune system is activated in HD, and two consequent mechanisms could be proposed to account for this. In the first instance, the altered immune profiles as detected in premanifest HD patients would suggest that immune activation takes place before neuronal degeneration. In an alternative scenario, the expression of mHtt could sensitize immune cells to overreact toward degenerating neurons and thus is more downstream in the disease process.
Anti-inflammatory therapies: concept and outcomes
If there is evidence that inflammation is involved in the pathogenesis of HD, then the obvious question arises as to what effect anti-inflammatory treatment strategies have on this condition. The effects of various anti-inflammatory drugs have been evaluated in genetic or toxin-induced mouse models of HD, 52 with inconsistent outcomes.
Minocycline in animal models of HD Minocycline is known to display high tolerance and excellent bioavailability to the brain and has been clinically tested for stroke, multiple sclerosis, spinal cord injury, amyotrophic lateral sclerosis and Parkinson's disease because of its known actions on suppressing microglial activation. Indeed, given its widespread neuroprotective and anti-inflammatory actions, minocycline has been extensively studied in various HD animal and tissue culture models (Table 2 ). In a first report from 2000, minocycline was shown to inhibit the upregulation of caspase-1 and caspase-3 expression and delay mortality in the transgenic R6/2 HD mouse model. 53 Notably, elevated inducible nitric oxide synthase expression observed in R6/2 mouse brains is consistent with that observed in HD patient brains 53 and so the neuroprotective effect of minocycline in these studies was linked to the reduced microglial activation resulting from the inhibition of inducible nitric oxide synthase and IL1b-converting enzyme. Following this initial study, Smith et al. 54 reported that minocycline inhibited huntingtin aggregation in a hippocampal slice culture model from the R6/2 mouse, but did not improve their motor performances on either the rotarod or grip strength tests. The neuroprotective effect of minocycline has also been further evaluated in the N171-82Q mouse strain. 55 However, the treatment did not improve survival, weight loss or motor function. Moreover, minocycline did not impact on ventricle enlargement nor striatal and cortical atrophy, thus manifestly failing as a treatment for HD in these animal models of disease.
Combined treatment using minocycline or alternative anti-inflammatory drugs The potential for combined therapy of minocycline with other anti-inflammatory agents has also been assessed in R6/2 mice. Daily intraperitoneal injections of minocycline prolonged survival, while a combined treatment with coenzyme Q10 as an antioxidant was even more effective. 56 Minocycline attenuated the microglial response but had no effect on weight loss or mHtt aggregation. Unlike minocycline, neither acetylsalicylate nor rofecoxib, used as anti-inflammatory agents, afforded neuroprotection in the R6/2 and N171-82Q transgenic mouse models. 57 Furthermore, when the R6/2 mice were treated with acetylsalicylate, significant weight loss was recorded and their life span was significantly decreased, indicating toxicity at the dose tested. The N171-82Q mice subjected to acetylsalicylate treatment also exhibited significant weight loss. Finally, in nontransgenic models of HD, Lewis rats lesioned with 3-nitropropionic acid (3-NP) or QA with minocycline treatment were protected against QA-induced striatal lesions but not against the toxicity induced by 3-nitropropionic acid. 58 Interestingly, in Sprague-Dawley rats lesioned with QA, the combined treatment of minocycline plus pyruvate inhibited inflammation, oxidative damage and neuronal loss. 59 Others have investigated the effects of minocycline on microglial proliferation related to N-methyl-D-aspartic acid receptor activation. 33 In order to confirm the benefits of minocycline, a comprehensive behavioral testing in the R6/2 mouse model was recently reexamined. 60 However, neither coenzyme Q10 nor minocycline had significant beneficial effects on measures of motor function, general health, body weight and survival. Higher doses of minocycline, on the contrary, curtailed survival in R6/2 mice. Taken together, previous studies of the effects of minocycline on animal models of HD have generated conflicting results as to their efficacy on behavioral outcomes and other measures, which may relate in part to the type of model being studied and the dose used.
Minocycline in clinical trials
The promising results of the early in vitro and in vivo reports on HD models, in addition to its clinical efficacy demonstrated for other diseases, have led to various trials testing minocycline in HD patients. In a first open-label safety and efficacy trial, 10 out of 14 HD patients treated with minocycline (100 mg day -1 ) showed an improvement in their Unified HD Rating Abbreviations: 3-NP, 3-nitropropionic; 4-HNE, 4-hydroxynonenal; 8-OHdG, 8-hydroxy-2'-deoxyguanosine; AIF, apoptosis-inducing factor; AIMS, abnormal involuntary movement Scale; b.i.d., twice a day; CHX, cycloheximide; CoQ10, coenzyme Q10; COX2, cylooxygenase-2; d, day; DC, doxycycline; HD, Huntington's disease; i.p., intraperitoneal; iNOS, inducible nitric oxide synthase; MMSE, minimental state examination; MC, minocycline; mo, month; QA, quinolinic acid; TNF-a, tumor necrosis factor alpha; TX, treatment; UHDRS, Unifed Huntington Disease Rating Scale; w, week; yrs, years.
In the 'outcome' column, blue boxes indicate absence of change, green boxes indicate improvements while red boxes highlight adverse effects. For color version of this table see online version.
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Scale motor score, especially in oculomotor function, fine motor tasks, chorea and gait. 61 These improvements were also associated with a stabilization of neuropsychological function after 24 months. 62 In striking disagreement with this study, two subsequent studies using higher doses of minocycline (200 mg day -1 ) showed good tolerance and apparent safety, but neither exhibited any improvement in these same HD features. 63, 64 Similarly, the most recent double-blind multicenter study of minocycline (100-mg capsules or matching placebo administered twice a day) did not generate any meaningful slowing of the rate of functional decline (DOMINO study, clinical trial NCT00277355). Compounding even further these unfavorable results, the safety of minocycline has recently been questioned when two-thirds of subjects who were administered the latter regimen of minocycline discontinued the drug after developing serious hyperpigmentation only 1 year into the 5-year treatment regime. 64 The discussion surrounding the therapeutic efficacy of minocycline in animal and cell models of HD, as well as in patients, has met with significant disagreement. Results from recent studies have been disappointing, indicating only moderate neuroprotective effects at best, which have also been associated with significant side effects in some instances. However, several factors may account for the discrepancies between the initial reports and the more recent observations: (1) Minocycline has multiple effects, 65 such as the blockade of nuclear factor-kappa B nuclear translocation, impaired microglia T-cell signal transduction 66 and 5-lipoxygenase inhibition. 67 The initial interest in the neuroprotective properties of monocycline was largely based on the anti-apoptotic properties of this drug. Subsequently, minocycline was investigated for its potential effects on inflammation, free radical damage, excitotoxicity and aggregation. The numerous targets of minocycline certainly complicate result interpretation. (2) The range of drug administration regimens, as shown in Table 2 , constitutes a major source of variation. The choice of doses, administration routes, as well as duration of treatment is not consistent between studies. For example, the dose used in experimental models varies from 22 to 100 mg daily orally or intraperitoneally. 68 However, given that minocycline passes through the blood-brain barrier by passive diffusion, 69 and that side effects begin with doses higher than 100 mg daily, this implies that maximum doses have already been tested in patients. (3) The choice of animal model is another source of variability. For example, the onset and progression of the disease in R6/2 mice is highly dependent on an unstable CAG repeat length, which has generated several different sub-colonies used in laboratories across the world. 70, 71 Moreover, the choice of promoter to drive the expression of the mHtt varies among HD mouse models. Similarly, the number of CAG repeats, as well as whether they express the full or truncated form of mHtt is another source of discrepancy between the different models 72 and can significantly alter the structure of mHtt. In addition, the toxin-induced HD models do not necessarily recapitulate all features of HD and these models generate an acute immune response that does not resemble the low chronic inflammation seen in patients with HD. In this regard, an anti-inflammatory drug could be more efficient in such animal models than in patients. (4) Finally, another source of discrepancy could relate to non-genetic effects on disease onset and progression. Although the size of the CAG repeat is a major determinant of the age of onset, 73 both other genetic and environmental parameters alter the age of onset, progression and severity of the disease. 74, 75 These observations originate, in part, from large kindred studies demonstrating that age of onset is attributable to genes (40%) and to a greater extent (60%) to environmental factors (exposure to pollutants). 74 In addition to the minocycline, salicylate and rofecoxib trials there is a single study that investigated corticosteroid therapy in HD. Dexamethasone treatment (4 mg daily for 20 days followed by 8 mg daily for an additional 20 days) in six female HD patients has demonstrated improvement of abnormal involuntary movements, and manual dexterity, as evaluated by the tapping test. Importantly, no observable side-effects were described. 76, 77 To date, the testing of anti-inflammatory drugs has been limited, some studies have shown promising results, while others have been disappointing. In order to refine anti-inflammatory strategies, it is therefore critical to understand why some treatments have been efficient in particular models of disease. For example, in the QA-lesioned animals, the mHtt is not expressed in microglia. Therefore, this model may not be appropriate for investigating the effect of antiinflammatory drugs on the dysfunctional immune system. On the other hand, the toxin-induced model of HD is relevant to address the inflammatory response induced by neuronal dysfunction and death.
Experimental strategies to decipher the role of immunity in HD Dissecting the contribution of the immune response to HD pathology, and fully understanding whether this phenomenon is a cause or a consequence of the disease, is not straightforward. Neuronal death triggers an immune response, which can be seen as a repercussion of the pathology. Evidence of elevated cytokine levels in pre-symptomatic patients, for example, certainly argues in favor of inflammation not being a consequence of brain disease 16 but rather a precursor of onset of pathogenic events. At the moment, it is still unclear whether a hyperreactive immune system is the cause or a consequence of the pathology.
Considering the data currently available, it is critical to experimentally address the role of the immune system to HD pathology, which may thereafter help define new therapeutic targets and design suitable drugs to alter the immune response efficiently. From the data presented in this review, one can conclude that the immune response is altered both in the CNS and in periphery in HD. Strikingly, blood cells and even lymphoblasts in the bone marrow demonstrate diverse alterations and dysfunctions. 78 On the one hand, this is not surprising considering that the huntingtin gene is highly expressed in immune cells. On the other hand, immune cells patrolling the body could encounter either mHtt or debris from dying cellular elements, which could in turn trigger an immune response.
Isolating immune cells from a healthy body, and examining whether these cells become dysfunctional in the HD environment would help decipher the intrinsic contribution of the immune system to HD pathology. Conversely, it would be very interesting to transfer mHtt expressing immune cells into a healthy animal to evaluate the potential toxic contribution of the immune system, as well as the reverse (that is, normal immune cells in transgenic mice models of HD). Accordingly, experiments addressing various aspects of this problem would require the development of chimeric mice (Figure 4a ). This methodology relies on the irradiation of recipient mice to remove bone marrow and subsequently replace it with hematopoietic stem cells originating from a donor animal. To test whether the immune system has a detrimental effect in HD mice, one could myeloablate recipient HD mice and graft hematopoietic stem cells derived from noncarrier mice (Figure 4b, left panel) . As negative controls, HD mice could be grafted with their own hematopoietic stem cells. If this procedure slows down the disease progression in chimeric mice, this would suggest that the immune system indeed has a detrimental role in HD mice.
If proven, then new anti-inflammatory drugs could be developed to inhibit this aberrant immune response. Importantly, if the noncarrier immune cells show an altered response when transferred into HD animals, it would suggest that the HD environment induces the aberrant immune response. Alternatively, the detrimental role of the immune system could be tested while transferring HD hematopoietic stem cells to myeloablated noncarrier mice, evaluating whether such mice develop features of the disease (Figure 4b , right panel). This would suggest that the intrinsic expression of the mHtt in HD immune cells likely contributes to the disease. Although this experimental strategy presents a number of important technical challenges, such as side effects generated by irradiation or progenitor depletion, which could influence the outcome, 79 it is still valuable to address the role of the immune system using this paradigm. With proper controls, this set of experiments could provide new directions to treat this incurable disease. It could also help in the search of new biomarkers of disease progression as well as diagnostic predictors. 80 
Perspectives
The relationship between the mHtt and inflammation/immunity is an emerging concept that is attracting increasing attention. As outlined in this review, the role of the immune response in HD is certainly gaining credence. Several studies have now provided evidence for an activation of the immune system in HD patients 11, 14, 16, 81 and animal models, 16 but few of the anti-inflammatory strategies undertaken thus far have led to meaningful benefits in patients. 61, 62, 64 Why is this? Could it be that the wide-spectrum anti-inflammatory drugs used in clinical trials to date did not work, because they suppressed both the detrimental (for example, pro-inflammatory cytokines, oxidative stress, and so on) and beneficial roles (for example, pro-repair processes, phagocytosis and neuroprotection) of the immune system in HD? Could targeting more specific facets of the immune systemfocusing on the induction of the neuroprotective role of the immune system and shutting down its proinflammatory features-yield a better outcome?
Many working in the field of neurodegenerative disorders, including HD, have dismissed the immune response to be peripheral to the disease process. However, there is no doubt that the immune system is activated in these disorders and the important question to answer now is why the immune system is activated; what effect does this really have on the disease course and how can it be modulated in order to develop new therapeutic strategies. Even considering cases where anti-inflammatory treatments in HD patients have yielded consistent and meaningful clinical outcomes, 61 treating a chronic disease with the long-term, sustained administration of a drug associated with serious side-effects, would at the very least be quite challenging. Future treatments should be designed to specifically promote the neuroprotective potential of the immune system. Thus, optimizing anti-inflammatory approaches to HD treatment is indeed still warranted and may have implications beyond this neurodegenerative disorder.
